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To all people with Cystic Fibrosis. 
  
When I started my work as a clinical psychologist at Stockholm’s CF-Center in 2008, one of 
my first main questions was about the mental health characteristics of the population I was 
expected to help. In the literature on mental health in adults with Cystic Fibrosis (CF) I found 
a few studies showing mixed results, and also that the adult CF population worldwide at that 
time was relatively young, had poor health status, and was small in comparison to the 
population of children with CF. However, the studies available at that time also reflected 
optimism and I remember an article describing a “changing scene”; in the future CF patients 
predominantly would be adults with a chronic condition and not children with a lethal 
disease. Compared to the CF population worldwide at that time, the Swedish CF population 
had a pronounced survival rate and good somatic health status; 50% were adults. However, 
the mental health of the Swedish adult CF population had never been evaluated. Since CF is a 
serious and demanding medical condition, it was easy to hypothesize that the patient 
population would exhibit elevated rates of anxiety and depression. Because CF is also a 
disease in which the outcome largely depends on patients’ ability to manage their treatment 
and self-care, I thought that the mental health  aspects of CF were of interest and importance 
to study.  
 
 
  
ABSTRACT 
Background: Cystic fibrosis (CF) is an autosomal recessive inherited, life shortening multi 
organ disease most typically affecting the respiratory system and the gastrointestinal tract. In 
recent decades progresses in the management of CF has led to an increasing proportion of 
adults with CF. Sweden has a large proportion of adults living with CF, however there is no 
systematic evaluation conducted, and thus a lack of knowledge regarding their mental health.                                                            
Aim: The overall aim with this thesis was to investigate the mental health among adults with 
CF, and to explore adult CF patients experiences of the CF treatment applied in Sweden.                                                                                                                              
Methods and Results: Paper I, a cross-sectional study. Comparisons of Hospital Anxiety 
and Depression Scale (HADS) data from 129 Swedish adult CF patients, and from published 
studies in Belgian, British and German adult CF-patients with corresponding general 
population data showed no elevated risks for anxiety or depression among the adults with CF 
in a binary logistic analysis. ANOVA showed a slightly elevated level of anxiety in the 
Swedish CF-sample, but this effect was only seen among the women. Paper II, a cross-
sectional study in 68 adults. Structural Equational Modelling (SEM) showed that those with 
severer cftr mutation classes with increasing age and a parallel deterioration of somatic health 
get poorer psychological wellbeing. Exercise had a positive effect on psychological 
wellbeing, but only if it also had a positive effect on somatic health. Paper III, a longitudinal 
study in 68 adults. Latent Growth Modelling (LGM) showed that anxiety, especially when 
combined with some level of depression, was associated with a faster decline in lung function 
over time. Paper IV, a qualitative study. Semi-structured interviews were conducted with 12 
‘middle-aged’ (32-55 years) adults. Inductive content analysis resulted in three themes: 
‘Prioritize and manage health – a life condition’, ‘Aspiration for and possibility to a ‘normal 
life’ and ‘The CF center as a partner in the life condition’.                                                                                                      
Conclusion: This thesis has contributed with an increased understanding of the mental health 
aspects of CF for adults. As a group, there is no elevated risk for impairment in mental health 
with regard to anxiety and depression in Swedish adults with CF. However, individuals with 
genetically more severe CF with age, and deteriorated health, get vulnerable for poor 
psychological wellbeing, and also those who are performing a high amount of physical 
exercise without maintaining their somatic health. Over time anxiety, when combined with 
some level of depression, seems to be associated with a faster decline in lung function. These 
mental health aspects can be deeper understood from the perspective that prioritization of 
health is (literally) a life condition for the adult with CF, and that the aspiration for and 
possibility for a ‘normal life’ can result in stressful conflicts, especially when health is 
deteriorating. In the coping with the life condition the CF center is seen a partner. Clinical 
implications should focus on the patients vulnerable for poorer mental health, and on 
including the patients’ perspective through person centered care (PCC) and a health 
psychological approach in the CF-care. Future research in the area of mental health in CF 
should broaden the perspective and focus also on the wellbeing aspects of mental health, and 
would benefit from having a more clearly defined health psychological framework thus 
including the study of behavioural patterns that underlie disease development and health.  
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1 INTRODUCTION  
Cystic Fibrosis (CF) is an autosomal recessive, life-shortening, multi organ disease leading to 
a progressive deterioration of health. Classical cases of CF affect the lungs and respiratory 
system as well as the gastrointestinal tract is affected, and chronic pulmonary inflammation 
and infections are the primary causes of mortality in CF (1). Earlier people with CF usually 
died during childhood; however, the introduction of centralized care, and multidisciplinary 
management of CF in the 1980’s, led to a dramatic improvement in health outcomes and 
survival rates in the subsequent decades (2).  
To date more than 50 % of the European CF population are adults (3). Recent forecasts show 
that the adult CF population will further increase remarkably in the coming years. Thus, in 
the future the dominating part of the patient population will be predominantly adults (4). 
However, health status and survival still differ considerably between countries were CF is 
prevalent. In Sweden the CF population as a whole enjoys a comparatively good somatic 
health status, high survival rate and pronounced longevity according to international 
comparisons and as a consequence a high proportion of the CF patients are adults (3).   
Despite the remarkable improvements in the management, treatment and health outcomes CF, 
is still incurable. The multidisciplinary treatment, to large extent based on self-care, is 
extremely time consuming and physically demanding for the patients especially when their 
health is deteriorating. For adults with CF, the total disease and treatment burden is high 
including the natural course of CF with disease progression, deterioration of health and 
comorbidities (5, 6). Adult CF patients invest a significant amount of time on daily self-care 
and treatment in order to maintain their health. This cost may have an impact on mental 
health and quality of life (QoL). People suffering from somatic diseases generally are at risk 
for negative impacts mental health (7), and thus this issue is important to address among the 
growing adult CF population. However, results and conclusions from studies of mental health 
in adults with CF are limited, mixed, sometimes inconsistent and often with a main focus on 
anxiety and depression. Furthermore, as there are differences between countries with regard 
to CF care, treatment regimens and health care systems the results of such studies are not 
fully generalizable. In the Swedish adult CF population there is no systematic evaluation 
conducted with regard to mental health, and thus a lack of knowledge. 
The overall aim of this thesis was to investigate mental health among adults with CF, and to 
explore their experiences with the CF treatment regimen used in Sweden and thereby increase 
the knowledge about how the multiprofessional CF care team can facilitate and support adult 
CF patients in maintaining their mental health.  
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2 BACKGROUND 
2.1 CYSTIC FIBROSIS 
Cystic Fibrosis (CF) is a life-shortening and incurable autosomal recessive disease. CF is 
congenital and chronic and the expected course is a progressive deterioration of health 
through malfunctioning of epithelial organs such as the lungs, pancreas and liver. (1). 
2.1.1 Epidemiology 
The incidence, or birth prevalence, varies across the world. In Europe the incidence of CF 
ranges from 1/1350 in Ireland (8) to 1/25 000 in Finland (9). Incidence of CF in the Swedish 
population amounts to 1/5600 live-births (10). In North America the estimated number of 
people with CF is 30 000 (11), and in Europe there is approximately 44 000 patients (3). 
Currently there are approximately 720 people living with CF in Sweden (12).  
2.1.2 History and Prognosis 
Historically CF has been a lethal disease among children. A quote on CF from the late 1800s 
observed, “the child will soon die whose brow tastes salt when kissed”. The disease was first 
described in 1936 and in 1948 the finding that became the basis for the method still used as a 
mainstay of diagnosing CF, the sweat test, was discovered. In 1985 the gene responsible for 
CF was localized, and in 1989 the gene was cloned and the protein, a chloride channel 
affected in CF, cystic fibrosis transmembrane conductance regulator (CFTR) was identified 
(2).  
During the four recent decades health outcomes, survival and longevity have improved 
remarkable thanks to the development of management, centralized care and multidisciplinary 
treatment, for CF. However, survival and prognosis vary greatly in countries where CF is 
prevalent, and internationally there are still people with CF who do not survive past 
childhood or young adulthood (3).  
2.1.3 Clinical implications 
Most significantly in classical CF extremely thick mucus that builds up in the lungs and 
blocks the airways, where the proliferation of bacteria results in repeated serious lung 
infections. Progressive pulmonary disease associated with chronic bacterial infection and 
inflammation is the major cause of morbidity and mortality in CF patients (1). Chronic 
pulmonary infection is also the main determinant of the disease burden in terms of quality of 
life (13). Since a substantial portion of the patients develops severe respiratory disease, lung 
transplantation is an established therapy for end-stage lung disease in CF (13, 14). However, 
symptom severity varies among individuals and organ systems, as well as with age.  
As mentioned previously, CF is a multi organ disease and also has other common 
complications and manifestations. The most common endocrine complication is CF related 
diabetes (CFRD), the prevalence of which starts to increase after the age of 10 and reaches 
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40-50 % in adults. Some individuals also develop severe CF related liver disease (CFLD), 
often during adolescence and before reaching 20 years of age (13-15). Approximately 5 % of 
the patients need a liver transplant (13). The gastrointestinal tract and pancreas are also 
usually affected by CF. Meconium ileus affects approximately 20 % of newborns with CF. 
Older patients may develop distal intestinal obstructive syndrome (DIOS), an occlusive 
manifestation with acute onset (13, 16). Pancreatic insufficiency (PI) causes malabsorption, 
especially of fat, which leads to malnutrition and poor growth and is seen in approximately 
90 % of the patients. PI is associated with a more severe CF phenotype and overall disease 
progression (17). Another complication in adults with CF is increased risk for gastro-
intestinal cancers the most prevalent being colorectal cancers (18, 19). There is also an 
increased cancer risk due to post-transplant pharmacological immunosuppressive therapy. 
Furthermore, male infertility due to Congenital Bilateral Absence of Vas Deferens (CBAVD) 
is found in up to 90 % of males with CF. In parallel with the progressive increase of survival, 
CF-related bone disease has emerged and is associated with factors such as malnutrition, low 
Body Mass Index (BMI) and severity of lung disease (13). Because CF is a complex and 
serious disease, it also can have an impact on the patients’ mental health; Anxiety is found in 
32-38 % of adults with CF, and depression in 10-21 %. Further descriptions and references 
are given in the section “Mental health in adults with CF”. 
2.1.4 The genetic background 
CF is caused by a mutation in the gene that codes the Cystic Fibrosis Transmembrane 
conductance Regulator (CFTR), a protein in the apical membrane of the cell surface that 
controls the salt and water balance across the cells. The protein is a chloride channel, and a 
defective CFTR causes malfunction in the chloride transport in the cell which leads to altered 
secretion in glands and organs. One example is the sticky mucus in the airways described 
above (13), (Fig. 1)  
 
Fig 1. The pathophysiology of CF. (Picture published with permission from Cecilia Rodriguez Hortal.) 
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To date more than 2000 mutations of the cftr gene are known and registered in a database 
(20, 21). The cftr mutations was originally grouped into five major classes based on their 
predicted functional consequences, with regard to protein synthesis and chloride channel 
functioning for the CFTR protein. Mutation classes I-III are called severe mutations 
(especially class I and II) as they cause total loss of chloride channel activity. These mutation 
classes are associated with a severe disease expression with regard to medical outcome. The 
most common cftr mutation belongs to class II. Since Classes IV-V maintain some chloride 
channel activity, they are called mild mutations as they are causing a milder manifestation of 
the disease (22-25). The classification has later been expanded with a sixth and a seventh 
class.  
The five originally described classes and their functional defect are (26) (Fig 2): 
2.1.4.1 Class I 
These mutations cause defective protein production. No full length CFTR protein is 
synthesized due to a premature stop, and no CFTR protein will reach the apical membrane at 
the cell surface. 
2.1.4.2 Class II 
Mutations in this class cause defective protein processing. The protein will not be properly 
processed and this defective protein will be recognized as abnormal. This leads to premature 
degradation, and thus the protein will in not be transported to the cell membrane. The most 
common cftr mutation F508del belongs to class II (13).  
2.1.4.3 Class III 
Class III mutations give defective regulation. The protein reaches the cell membrane but is 
non-functional due to suppression of chloride channel activity. They are called gating-
mutations. 
2.1.4.4 Class IV 
These mutations cause defective conductance. CFTR are found at the cell membrane, but 
abnormal conformation of the opening in the channel leads to disrupted ion flow.  
2.1.4.5 Class V 
Class V include mutations that cause reduced synthesis or functioning because there is a 
reduced amount of CFTR or functional CFTR at the cell membrane.
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Fig. 2 The five cftr mutation classes originally described and their functional consequences for the protein 
synthesis and chloride channel functioning. (Picture published with permission from Anne Geborek.) 
2.1.5 Management and treatment 
2.1.5.1 The centralized and multidisciplinary approach 
The complexity of the disease requires a multicomponent treatment approach (27). About 
four decades ago, the CF care became centralized, and a more intensive treatment was 
introduced, using a multifactorial, interdisciplinary approach (2). This approach has, as 
mentioned, been successful with regard to improved health outcomes, life expectancy and 
survival. The management and treatment of CF is currently multidisciplinary and provided in 
specialized centers, according to continuously updated international evidence based 
guidelines (14, 28-30).  
2.1.5.2 Treatment  
Because CF is still incurable, the treatment is preventive and symptomatic and aims to 
maintain health and postpone the progress and harmful effects of the disease. It is well known 
that the treatment is complex, extremely time consuming and physically demanding for the 
patients (5), since it is largely based on daily self-care. International guidelines describe 
treatment and management of CF from a multidisciplinary approach (28). The cornerstones 
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of the modern CF treatment are airway clearance, antibiotic therapy, nutrition and (27). 
Below is an overview of certain essential parts of the recommended treatment regimen.  
Physiotherapy in the format of airway clearance, physical exercise and inhalation therapy - 
plays an important role in maintaining health in CF patients (31). Physiotherapy should be 
performed regularly and frequently from the time of diagnosis. The aim of these interventions 
is to maintain ventilation of the lungs, to postpone the progression of pulmonary disease, and 
to prevent musculoskeletal complications (32).  
Among all the different medical treatments, one mainstay in the modern CF care is 
preventive and frequent/regular use of intravenous antibiotics for the treatment of airway 
infections. Antibiotics are also administered orally or via inhalation. Since good nutritional 
status is positively associated with lung function and survival it is essential to maintain a 
normal BMI (32-34). In people with CF, this is achieved through a high caloric intake, 
pancreatic enzymes and supplementation with minerals, fat-soluble vitamins, and fatty acids 
(35, 36).  
Furthermore, regular medical check-ups are necessary to detect signs of complications early 
on. Psychosocial support  and screening for and treatment of anxiety and depression (30, 37) 
are also recommended parts of the management of CF. This is further described in the section 
“Mental health care and psychosocial support in CF care” below.  
2.1.5.3 New, CFTR modifying treatment 
Current standard treatment is as mentioned developed to target the symptoms caused by the 
defective cftr gene. In recent years pharmacotherapy that aims to increase the function of the 
CFTR protein has been developed. This CFTR modifying treatment could make a substantial 
difference in changing or stopping the disease process. Two drugs, Orkambi® and 
Kalydeco® (38, 39), are now recommended as parts of standard of care for patients with the 
cftr mutations in question (30). Kalydeco®, the first of these two drugs to be approved (40-
43) is targeting cftr gating mutations found in less than 5 % of the CF-patients worldwide. 
Orkambi® is targeting the most prevalent cftr mutation worldwide, F508del. Symkevi® is 
also targeting F508del, gives less side effects, and is recently approved by U.S. Food and 
Drug administration (FDA) (44) and European Medicines Agency (EMA) (45). Clinical 
pharmaceutical studies of a three-drug combination to treat individuals heterozygous for the 
F508del CFTR mutation is currently underway. (46). 
There is an on-going European research project to develop ‘tailored’ treatments for adults 
with extremely rare cftr mutations who cannot otherwise get access to the cftr modifying 
treatment. In this project patient derived organoids are used for laboratory testing of drug 
candidates targeting the basic defect in cftr. Patients will be assigned to clinical trials using a 
suitable drug candidate based on the reaction in their respective organoids (47).  
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2.1.5.4 CF care in Sweden 
In Sweden the CF care has been centralized since the 1970s. Currently, people diagnosed 
with CF are referred to one of the four Swedish CF centers (Stockholm, Uppsala, Lund, 
Gothenburg) offering multidisciplinary care. In line with the international guidelines 
mentioned previously, the care involves frequent clinical evaluations and monitoring for 
complications, and the treatment regimen described above. In the Swedish treatment regimen 
a focus both on proactive treatment and on giving the CF patients the possibility to a normal 
life were and still are important strategies in the Swedish CF treatment regimen (48). Since 
the early 1980’ the Swedish CF treatment regimen has emphasized physiotherapy as an 
essential component in maintaining healthy functioning. Physiotherapy is introduced from the 
day of diagnosis and managed by the patient as part of their daily self-care routine. Treatment 
includes daily airway clearance therapy based on physical exercise and chest physiotherapy 
along with frequent physical exercise (49). Furthermore, home administered intravenous (IV) 
antibiotic treatment for early eradication of pathogens is also part of the standard of care for 
CF since the 1980s (50, 51), as well as a strong focus on nutritional issues including 
intravenous supplementation with polyunsaturated fatty acids (PUFAs) (52). The IV 
antibiotic treatment supplies and drugs are distributed from the CF center but managed by the 
patients in their daily life at home, at work or in school. In many countries, this kind of 
treatment is given during hospitalization. 
2.2 CF IN ADULTS 
The advances in the management of CF the last decades have led to an increasing proportion 
of adults with CF (53). The picture of CF as a lethal disease in children has changed, and the 
CF population is now predominantly an adult one (53). In Europe, today 52 %  of all the CF-
patients are adults (3). In Western Europe an increase by 75 % in adults with CF is predicted 
by 2025 (4).  
In parallel with a growing adult CF population, the complexity of the CF-care and treatment 
is increasing (53). These circumstances mean that CF care needs to be adapted to meet the 
physical and psychological needs of this “new”, older population. As the primary literature on 
CF care for adults has been limited, an international task force has been working with 
priorities for optimizing adult CF care over the next 15 years (53).   
2.2.1 The Swedish adult CF population 
In an international perspective the Swedish CF-population as a whole enjoys a good health 
status, pronounced longevity and high survival rate  – and as a result a comparably high 
proportion of adults. (3). Out of the 720 CF-patients in Sweden 65 % are adults, and 56% of 
the adults are over 30 years of age (54). In the entire Swedish adult CF population 18 % have 
received a lung- or liver transplant (12).  
Furthermore, the life expectancy in Swedish CF-patients is to date estimated to be 
approximately 50 years according to the latest calculation (10). However, the median age of 
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Swedish people who have died of CF between 2010-2017 is 39 years (12). In Sweden the 
estimated increase of adults with CF is 59 % by 2025 (4).  
2.2.2 Psychosocial challenges for adults with CF 
Adults with CF face many psychosocial challenges potentially having an impact on mental 
health and quality of life. It is concluded that they carry both a substantial physical and 
psychosocial burden to adhere to their treatment regimen while they also are trying to live 
“normally” (55). The treatment regimen is complex and demanding especially as the disease 
gets progressively more severe (5, 56). The comorbidities mentioned is also a factor that 
increases the total burden of disease and treatment, since some of them are becoming more 
prevalent with age. Other challenges for both men and women are issues of reproduction and 
fertility. Another challenge is coping with the impact of disease management and 
deteriorating health on family relationships, employment and education. In the most severe 
stages of the disease respiratory failure, requirement of supplemental oxygen, and lung 
transplantation are unavoidable challenges (53).  
2.3 MENTAL HEALTH IN ADULTS WITH CF    
When the concept “mental health” is used in the area of CF it has in recent decade to large 
extent addressed anxiety and depression as a main question of interest through international 
prevalence studies, international task forces and international guidelines in the area. 
2.3.1 Anxiety and Depression 
Dealing with a disabling life-shortening physical disease such as CF will occasionally cause 
feelings of worry and sadness as natural reactions. If these feelings or emotional states 
become pervasive, an anxiety or depressive disorder may develop.  Especially depression is 
associated with poor adherence to treatment, while the effects of anxiety on adherence is 
unclear (57). The typical symptoms and behavioral and cognitive components of depression, 
but also sometimes in anxiety (described below), are contradicted to ability to initiative with 
regard to a complex and demanding treatment routine that must be followed daily.  
2.3.1.1 Definitions of anxiety and depression 
Anxiety is a common mental health problem. Anxiety disorders are characterized by feelings 
of fear and anxiety, along with related behavioral disturbances such as avoidance. Other 
symptoms of anxiety include restlessness, irritability, reduced concentration and memory, 
sleep disturbance, fatigue, and muscle tension (58).   
Another common mental health problem is depression. Common symptoms of depression 
include sad, empty, or irritable mood, together with somatic and cognitive changes that 
significantly impair the capacity to function normally. Other symptoms and diagnostic 
criteria that often appear alongside the above include loss of interest, depressed mood most of 
the day, significant weight loss/gain, decrease or increase in appetite, fatigue or loss of 
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energy, withdrawal from activities, feelings of inappropriate guilt and/or worthlessness, and 
recurrent thoughts of death, and suicidal ideation/plans/attempts (58).  
Both anxiety and depression are associated with many physical diseases. A patient is 
diagnosed with “anxiety/depression due to another medical condition” when they suffer from 
a medical condition known to induce anxiety or depression and when that medical condition 
preceded the onset of anxiety or depression (58).  
2.3.1.2 Anxiety and depression in somatic diseases  
Despite methodological differences it can be concluded that people suffering from somatic 
diseases are at risk for anxiety and depression (7). For example, the prevalence of depression 
is for example markedly and consistently higher in people with diabetes mellitus, heart 
disease, cancer, stroke, rheumatoid arthritis and osteoporosis according to a review in the area 
(7). Similarly, patients with chronic respiratory diseases are generally at increased risk for 
anxiety and depression (59-61). However, prevalence differs among diseases, and depending 
on type of disease, disease stage and prognosis (7).   
2.3.1.3 Anxiety and depression in adults with CF compared to general populations  
Some studies have explored anxiety and depression in adults with CF, but their results and 
conclusions vary and in some cases are inconsistent. According to some studies, anxiety, and 
depression are common in people with CF (62, 63); a review concluded that there were 
higher rates of depression in CF patients at all ages than in healthy populations (64). Another 
review reports evidence for an increased risk of mental health problems among adults and 
adolescents with CF. On the other hand, the same review also concluded that psychological 
functioning in CF patients is similar to that of healthy people until the more severe stages of 
the disease (65). Similarly, two other studies concluded that rates of anxiety and depression in 
adults with CF are in line with those of the general population (66, 67), and the only Swedish 
study on the topic found mental health problems to be rare among in adult CF patients (68).  
The International Depression Epidemiological Study (TIDES) is a multicenter initiative 
involving nine countries, among them Sweden (Study I in the present project is partly based 
on Swedish TIDES-data); it has concluded that rates of anxiety and depression among adult 
CF patients are high (69). However, this study does not include any comparisons with data 
for the general population. Furthermore, questions have been raised about tools and 
methodology used in this study and also the need for a further discussion (70, 71). 
Conclusions about high rates of anxiety and depression among adult CF-patients compared to 
the general population are also made in a Spanish multicentre study with data from the 
Spanish arm of TIDES (72) and in a German multicentre study with German TIDES-data 
(63). On the other hand a large multicentre study performed in the UK based on the UK 
TIDES-data showed similar anxiety and depression rates among CF-patients as in the general 
population (73).  
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2.3.1.4 Prevalence of anxiety and depression in adults with CF 
Regarding anxiety and depression prevalence estimates, the “TIDES” study mentioned above 
reports an anxiety prevalence of 32 % and a depression prevalence of 19 % among adult CF 
patients across countries. Two multicentre studies based on TIDES data from the UK (73) 
and Germany (63) report anxiety prevalence of 34 % and 20.6%, respectively, and depression 
prevalence of 13 % and 9.6 %. Two single-centre studies conducted in Belgium (67) and in 
the UK (74) report anxiety in 30 % and 33 % of the patients, respectively, and depression in 
13 % and 16 %. Furthermore, a small US’ single-centre study (75) report a depression 
prevalence of 30 % and in a recent Danish study among young adults a similar depression 
prevalence was found, 32.8% (76). Results from the mentioned Spanish multicentre study 
show an anxiety prevalence of 29.7 % and a depression prevalence of 12.2 % (72). In the 
Italian arm of TIDES the prevalence of anxiety was 38.4 % and of depression 17 % (77).  
2.3.1.5 Factors associated with anxiety and depression in adults with CF 
Depression in adults with CF is consistently reported to be associated with low lung function 
(63, 69, 74, 75, 77) and low health related quality of life (72, 74-76). Depression is also 
concluded to have an impact on the course of lung function over time (78). In adult CF 
patients, negative associations were found between depression and treatment adherence (62, 
69, 79). Furthermore, depression is found associated with older age, recent use of IV-
antibiotics, haemoptysis or pneumothorax (69), being on the list for lung transplant (63, 69) 
and low educational level (72).  
Anxiety in CF populations has been found, contradictorily, to be either more common in 
women (63, 69, 72, 77, 80), or more common in men (66). In the large UK study men with 
CF were more anxious than healthy subjects, this effect was not seen among the women (73). 
Furthermore, anxiety is associated with more severe lung symptoms (63, 74), older age, 
lower BMI, lower lung function (77), hemoptysis or pneumothorax, being on the waiting list 
for lung transplant (69) and difficulties in relations (74).  
Other studies have found that neither age, sex nor disease severity are associated with 
depression and anxiety (66, 81), and Bergsten-Brucefors, Hjelte (68) found no association 
between disease severity and mental health problems in Swedish adults with CF.  
2.4 HEALTH RELATED QUALITY OF LIFE IN ADULTS WITH CF 
Two studies have compared global QoL between CF patients and general population/healthy 
people and arrived at opposite conclusions, one finding that people with CF report lower QoL 
than healthy people (82), while the other found that CF patients have a higher QoL than the 
general population/Health controls? (83). A recent Danish study found lowered HRQoL 
among young adults with CF (76).  
HRQoL has been investigated in adults with CF, often with a focus on associations with 
clinical variables and/or demographic factors. A recent review of the topic among adults and 
adolescents conclude that lung function - FEV1% - is the most-studied factor in relation to 
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HRQoL and was consistently associated with multiple domains of the measurements used. 
Other studies have found that lung function (83), disease severity (84), and medical factors 
and social circumstances (85) have associations with HRQoL. It has also been found that 
women report lower HRQoL than men [75]. According to the above-mentioned literature 
review, higher age is associated with a higher treatment burden, something that is one domain 
of HRQoL (86). 
Researchers have undertaken a handful of longitudinal studies on this topic, one of which 
concluded HRQoL is independent of changes in lung function over time among adults and 
adolescents with CF (85). In contrast, another study did find associations between changes in 
clinical variables and HRQoL over time (87). Another study found associations between 
survival and physical functioning, one of the domains of the HRQoL measurement used (88). 
A few studies have explored the complex relationship among HRQoL anxiety and 
depression, and lung function in adults with CF. Among adults and adolescents, life 
satisfaction (LS) - a measure related to QoL - was found positively associated with lung 
function and negatively associated with anxiety and depression (89). Similar results were 
obtained in a study among adults (75). Also, one study found an association between HRQoL 
and lung function while another found an association between HRQoL and anxiety and 
depression (67, 74).  
A very recent study found and concluded associations between “positive mental health and 
well-being” and HRQoL in adults with CF (90).  
 
2.5 MENTAL HEALTH AND PSYCHOSOCIAL SUPPORT IN CF CARE 
2.5.1 International guidelines  
International guidelines addressing mental health issues in the CF-care have in recent years 
been developed and published based on the results of studies investigating anxiety and 
depression in CF patients (37). These guidelines recommend routine screening for anxiety 
and depression - either annually or when clinical concerns arise - for CF patients starting at 
the age of 12, and for caregivers to children with CF. The guidelines also recommend that 
individuals who are identified to have depression/anxiety should receive further 
psychological assessment to form the basis for the choice of adequate treatment. Patients or 
caregivers found to have mild depression and/or anxiety should receive education and 
preventive or supportive psychological interventions, and should be rescreened on a periodic 
basis. Those who are found to have moderate or severe depression or anxiety should be 
offered evidence-based psychological treatment and/or psychopharmacological treatment. 
These guidelines also describe CF-specific issues with psychopharmacological interventions, 
since the pharmacokinetics of medications may be altered in CF, and make associated 
recommendations (37).  
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2.5.2 European guidelines  
European guidelines recommend psychological and psychosocial support as part of CF 
management (30). This recommendation emphasizes the fact that the disease is lifelong and 
demanding and will entail times of pronounced need for psychosocial support: for example, 
at diagnosis, during the transition to adult care, and at transplant or end-of-life. Key areas that 
merit qualified psychological intervention (i.e., care from a licensed psychologist) include 
adherence issues, anxiety and depression, pain, demoralization, aging with CF, disordered 
eating and/or body image problems, and anxiety and phobias connected to treatment 
procedures. There are also recommendations for mental health screening, assessment and 
treatment in alignment with the above described mental health guidelines in CF. Mental 
health professionals (i.e. lic. psychologists or psychiatrists) in the CF care should also provide 
support for CF team colleagues in their work with patients. The European guidelines also 
emphasize that multi-disciplinary care teams at CF treatment centers should include a 
licensed psychologist responsible for the psychological care (16, 32).  
2.5.2.1 Guidelines concerning key psychosocial issues of adulthood 
The latest update of the European guidelines  adds a special section focusing on how to 
address key psychosocial issues of adulthood and of growing older with CF, as these 
challenges can have a negative impact on mental health, self-esteem, and interpersonal 
relationships (30). These issues are:  
- How CF compounds normal psychological development 
- Decision-making concerning treatment, procreation, parenting, and vocational and 
career plans  
- Coping with health deterioration and its physical consequences such as loss of 
independence and mobility, and new complications or diagnoses 
- Coping with end-stage disease, transplant procedures, and end-of-life care. 
These guidelines further highlight the risk or likelihood of demoralization as a consequence 
of severe health problems (30). 
Key approaches described in the guidelines are being pro-active during routine clinical visits 
for early identification of psychological difficulties. Furthermore, promoting positive coping 
strategies for supporting adjustment to the disease, and fostering resilience is described as 
extra important. Also referral to the CF team psychosocial professional or external mental 
health specialist are highlighted as key approaches (30).   
2.5.3 Interventions 
To date there are no specific psychological interventions recommended for people with CF. A 
Cochrane review of the area that included studies among children, adolescents, and adults 
found insufficient evidence for specific psychological interventions (91), this was concluded 
due to the heterogeneity of studied interventions and methodological issues. However, it did 
find preliminary evidence for interventions targeting specific aspects of CF treatment. 
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According to this review, no specific studies of interventions for people with CF and 
comorbid mental disorders had been conducted (91). Another review focused on 
Motivational Interviewing (MI) for adherence problems in CF and concluded that MI could 
be a useful approach for healthcare professionals in communicating treatment issues in ways 
that facilitate adherence (92). Furthermore, the mentioned international task force for the CF 
care of adults also suggests MI and cognitive behavioral therapy (CBT) when dealing with 
non-adherence (93).  
2.6 THEORETICAL FRAMEWORK 
CF treatment and management seeks to maintain health by postponing and preventing the 
harmful effects of the disease. The WHO defines health as “a state of complete physical, 
mental, and social wellbeing, and not merely the absence of disease or infirmity" (94). 
Although this definition has been criticized, it does point out the importance of a 
multidimensional approach to health and also highlights different aspects of wellbeing. The 
biopsychosocial model of health (Fig.3) similarly offers a broader definition of health (95) 
and forms the overarching theoretical framework for this project. 
The aim with the project was not to test theories. However, it was considered relevant to use 
the biopsychosocial model of health and also a health psychological perspective to set the 
project in a broader context of health.  
2.6.1 The Biopsychosocial model of health 
An alternative to the traditional biomedical model of health emerged in the 1970s: the 
biopsychosocial model (95). In contrast to the biomedical model of health, in which disease is 
seen as being a result of biological deficiency or damage, the biopsychosocial model presents 
a broader perspective on illness and health that considers psychological factors, patient 
behavior, and the patient’s cultural and social context.  
The biopsychosocial model of health considers the relation between the concepts of health 
and disease to be a complex one: “The boundaries between health and disease, between sick 
and well, are far from clear and will never be clear, for they are diffused by cultural, social 
and psychological considerations” (95). 
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Fig. 3 The biopsychosocial model of health 
The biological factors causing CF are now known, and treatments targeting these biological 
effects and symptoms have led to improvements in somatic health for people with CF, 
resulting in a growing adult CF population. However, this improvement in somatic health 
comes at the cost of a very complex treatment regimen, leading to a high treatment burden, 
especially for adult patients, and a resulting impact on the patients’ health-related quality of 
life. Similarly, although the CF population has seen improved health status as a result of 
these treatment advances, adult CF patients in general struggle with the progress of the 
disease, deteriorating health, and the development of comorbidities, resulting in a high 
disease burden that impacts patients’ psychosocial life. Using the WHO definition and the 
biopsychosocial model of health, it can be said that people with CF have achieved improved 
physical and biological health, but there is a need of systematic knowledge about  
psychological and social health/needs in the growing adult CF population .  
2.6.2 Health psychology 
A health psychological perspective helps us to further understand both health outcomes and 
needs with regard to efforts to improve health in a patient group. Health psychology was 
early defined as “the aggregate of the specific educational, scientific, and professional 
contributions of the discipline of psychology to the promotion and maintenance of health, the 
prevention and treatment of illness, the identification of etiology and diagnostic correlates of 
health, illness and related dysfunction, and the analysis and improvement of the health care 
system and health policy formation” (96).  
In the field of health psychology, “adjusting to chronic illness” is a familiar term. It has, 
however, been concluded that there is no consistent definition of adjustment and that there is 
a need for a “unified theory” (97). For example mental health and psychiatric approaches 
most commonly define adjustment in terms of absence or presence of a diagnosed 
psychological disorder, psychological symptoms, or negative mood (97).  In addition, 
positive affect and perceived personal growth as indicators of adjustment have been 
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investigated (98). The foundation for identifying determinants of adjustment to chronic 
conditions are theories of stress and coping, self-regulation, and social processes (98). 
Distinguishing between disease and illness can also contribute to further understanding of 
adjustment to a chronic condition. Disease refers to the biological processes affecting the 
person, whereas illness refers to the individual’s experience of the disease, thus including 
both its psychological and social effects (99). Adjustment to chronic disease goes beyond the 
physical impact and symptoms of the disease and includes the individuals’ perception, 
assessment, and adaption to the symptoms (99). 
With the biopsychosocial model of health and the perspective of health psychology in mind, 
we can assume that a serious chronic condition like CF will have an impact on patients’ 
psychosocial life. This, in turn and in some cases, may have an impact on somatic health 
outcomes. We can also conclude that psychological and social factors can have an impact on 
the treatment outcome of a disease. CF is a hereditary and congenital disease, and currently 
we have a great deal of biologically based knowledge - for example, genetic, medical, 
nutritional, and physiotherapeutic - on how to treat the disease. However, health outcomes for 
CF patients also largely depend on the individual’s capacity to manage treatment and perform 
self-care: that is, to engage in health-related behaviors. A challenge especially for adults with 
CF as the treatment complexity and treatment burden increases with age and disease 
progression. 
2.6.3 Definitions 
Below definitions of concepts used in the context of mental health in this thesis are given. 
There are, however, a variety of descriptions and definitions of the different concepts in the 
literature. As stated in the HRQoL paragraph below, there is sometime difficult to distinguish 
them from each other, as there are overlaps and similarities. As also pointed out, the concepts 
are wide and broad in their definitions.  
2.6.3.1 Mental health 
Mental health is a concept with a broad definition according to WHO; “a state of well-being 
in which the individual realizes his or her own abilities, can cope with the normal stresses of 
life, can work productively and fruitfully, and is able to make a contribution to his or her 
community” (100). 
2.6.3.2 Health related quality of life 
When referring to quality of life in the context of health and/or disease the concept HRQoL is 
used and focuses on the quality-of-life consequences of health status, and includes domains 
related to physical, mental and emotional, and social functioning (101). However, the 
literature employs a variety of definitions of QoL, HRQoL, and health, making it is 
problematic to distinguish among them (102).   
WHO for example defines “Quality of Life” (QoL) as ”an individual's perception of their 
position in life in the context of the culture and value systems in which they live and in 
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relation to their goals, expectations, standards and concerns” and notes that it “is a broad 
ranging concept affected in a complex way by the person's physical health, psychological 
state, personal beliefs, social relationships and their relationship to salient features of their 
environment” (103). 
2.6.3.3 Psychological wellbeing 
One theoretical model of psychological well-being encompasses six dimensions (104); 
“Autonomy” that includes components such as independence and self-determination. 
“Environmental mastery” is an individual’s ability to create or choose environments suitable 
to her/his conditions, “Purpose in life” means having a sense of direction and intention in 
life, contributing to a feeling that life has a purpose and meaning. “Self-acceptance”, or 
positive attitudes towards one-self. “Personal growth”, or continued development of one’s 
potential, and growth as a person. “Positive relations with others” emphasizes warm, trusting 
interpersonal relationships (104). 
2.7 IN SUMMARY  
In summary I have identified the following research gaps I aim to investigate by this thesis: 
- There is no systematic knowledge about the mental health in Swedish adults with CF. 
- There is a lack of knowledge regardning how the Swedish adults with CF experience 
their intensive, daily, multifactorial treatment regimen. 
- Therefore there is also insufficient knowledge about how to facilitate and support the 
adult CF-patients. 
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3 AIMS  
3.1 GENERAL AIM 
The overall objective of this thesis was to investigate mental health among adults with CF, 
and to explore their experiences with the CF treatment regimen used in Sweden and thereby 
increase the knowledge about how the multiprofessional CF care team can facilitate and 
support adult CF patients in maintaining their mental health.  
3.2 SPECIFIC AIMS 
3.2.1 Study I 
The aim of study I was to estimate prevalence and degree of anxiety and depression among 
Swedish adult CF patients and compare it with Swedish general population data. An 
additional aim was to put the Swedish results in a context and compare the Swedish data with 
previously published anxiety and depression prevalence data from adult CF populations in 
three other European countries (UK, Germany and Belgium) and corresponding general 
population data. 
3.2.2 Study II 
The aims of study II were to examine the associations between: 1. Type of cftr mutation 
class, medical status and psychological wellbeing; and 2. Physical exercise, medical status 
and psychological wellbeing in adults with CF. 
3.2.3 Study III 
The aim of study III, a longitudinal study, was to investigate the effects of anxiety and 
depression symptoms on the development of somatic health status parameters over time in 
adults with CF. 
3.2.4 Study IV 
The aim of study IV was to qualitatively explore “middle aged” (here defined as 30-55 years 
of age) adults with CF experiences of their intensive daily multifactorial symptomatic 
treatment regimen. 
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3.3 RESEARCH QUESTIONS 
3.3.1 Study I  
à What is the prevalence and level of anxiety and depression in Swedish adults with CF?  
à Is the prevalence and level of anxiety and depression in adults with Cystic Fibrosis higher 
than in the general population in Sweden, Germany, the UK and Belgium? 
3.3.2 Study II  
à Is a more severe cftr mutation class associated with worse psychological well-being in 
adults with CF?  Could this expected association also be predicted that the effect of mutation 
class on psychological wellbeing is mediated by medical status? 
à Does physical exercise have an association with psychological well-being in adults with 
CF? And is the expected association mediated by medical status? 
3.3.3  Study III 
à Are levels of anxiety and depression affected by previous levels and development in 
somatic parameters? 
àDo levels of anxiety and depression have prospective effects on subsequent development in 
clinical somatic parameters?   
3.3.4 Study IV 
à How do Swedish ‘middle-aged’ CF-patients’ experience their intensive daily 
multifactorial symptomatic treatment regimen? 
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4 METHODS 
 
An overview of the design, inclusion criteria and patient characteristics of the studies are 
given in table 1.  
Table 1: Characteristics of the four studies in the thesis.  
 Study I Study II Study III Study IV 
Design Cross-sectional Cross-sectional Longitudinal Qualitative 
Inclusion 
criteria 
+18 years, 
confirmed 
diagnosis of CF, 
nontransplanted  
+18 years, 
confirmed 
diagnosis of CF, 
known cftr 
mutation class, 
nontransplanted 
+18 years, 
confirmed 
diagnosis of CF, 
known cftr 
mutation class, 
nontransplanted 
+30 years, homo-
/heterozygous for 
mutation class I 
and/or II, 
nontransplanted, 
Swedish 
language 
Sample size N = 129 N = 68 N = 68 N = 12 
Gender 50 % women 46 % women 46 % women 58 % women 
Age (years, 
range) 
M=30.4 (SD 
11.73), 18-70  
M=33 (SD 
11.1), 19-65  
M=33 (SD 
11.1), 19-65  
MD=43, 32-55  
Lung 
function, 
FEV1 % pred. 
M=73.3 (SD 
27.3), 22-125 
M=71.7 (SD 
28.1), 20.6-
123.3 
M=71.7 (SD 
28.1), 20.6-
123.3 
MD=46, 30-96 
Data analysis ANOVA 
Binary Logistic 
Regression 
analysis 
Structural 
Equational 
Modelling 
Latent Growth 
Modelling 
Inductive 
Content Analysis 
4.1 DESIGN  
Studies I and II were cross-sectional studies. Study III had a longitudinal design and in Study 
IV used a qualitative approach/methodology.  
4.2 STUDY SAMPLES 
Study I was a multi-center study - the Swedish arm of TIDES (105) - and the participants 
were recruited from three of Sweden’s’ four Swedish CF centers: Stockholm, Gothenburg 
and Lund. The inclusion criteria were ³18 years of age and a confirmed diagnosis of CF. 
Transplant recipients were excluded. Of the 249 individuals who fulfilled the inclusion 
criteria for Study I 129 agreed to participate in the study. In addition, data from similar 
published studies performed in the UK, Germany and Belgium as well as corresponding 
normative sample data, were included for comparisons with the Swedish CF sample.  
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Studies II and III used the same study sample. Participants were recruited from Stockholm 
CF-center. Inclusion criteria were ³18 years of age, a confirmed diagnosis of CF and a known 
genotype. Individuals who had undergone transplants were excluded. Of  91 potential 
subjects 68 participated in the studies.  
In Study IV the participants were recruited based on purposive sampling from Stockholm CF 
center. The inclusion criteria were adults, ³30 years of age, solely attending Stockholm CF-
center, and being homo-/heterozygous for class I and/or II cftr mutation. Transplant recipients 
were excluded. Individuals not able to communicate in Swedish or not living in Sweden were 
excluded. For this study 23 patients met the inclusion criteria, and 12 participated. 
Participants in Studies I-III were recruited consecutively in connection with their routine 
outpatient clinical visit at their CF center during the period March 2008 – February 2009. In 
study IV participants were recruited from April to May 2018, and the interviews were 
conducted between May 21 and October 16 2018. 
4.3 PROCEDURE 
In Studies I-III individuals who met the inclusion criteria received information about the 
studies by a regular mail and were then contacted by phone with information and asked to 
participate. For those who agreed to participate a meeting with the CF center psychologist or 
social worker was scheduled in connection with a routine clinical visit to the CF center. 
During this meeting the participant completed the written informed consent and the 
questionnaires for the mental health outcome measures (further described in the 
Measurements section). For participants who displayed indications of elevated levels of 
psychological distress (i.e. anxiety and depression), the psychologist followed up/offered 
further psychological assessment. However, this follow up/assessment was not included in 
the studies.  
In Studies II and III the mental health outcomes were analyzed in relation to somatic 
parameters in order to answer the research questions. The completion of the above-mentioned 
questionnaires was therefore followed by a medical check-up in which the somatic 
parameters lung function, Forced Expiratory Volume in one second of predicted value (FEV1 
% predicted) and Body Mass Index (BMI) were measured. Data were completed from the 
Swedish CF registry with the measures of the somatic parameters as indicators of level of 
chronic inflammation/infection; Immunoglobulin G (IgG), and physical capacity; Physical 
Working Capacity (PWC) based on the corresponding annual check-up. In Study II, the 
measures, FEV1% predicted, BMI, IgG and PWC were together used as a proxy for “medical 
status”. In Study III these parameters were used both as predictors of subsequent levels of 
anxiety and depression and as possible consequences of previous levels of anxiety and 
depression. In Study II, information about cftr mutation class was taken from the Swedish CF 
registry. 
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In Study III the measures FEV1 % predicted, BMI, IgG and PWC were annually followed up 
on six occasions (annual check-ups). To explore whether anxiety and depression levels in 
2008 had an association with previous development of the somatic status, the corresponding 
somatic measures were taken from the Swedish CF registry for the years between 2002 and 
2007 as well.  
In Study IV individuals who met the inclusion criteria were contacted by phone by the study 
coordinator at the CF center with information about the study and asked to participate. If they 
were interested in participating they received further information by regular mail and were 
contacted by the interviewer to schedule the interview. In the interview meeting the  written 
study information was reviewed, and the participant completed the consent form before the 
interview started. The interviews were conducted by licensed two psychologists working in 
Swedish CF-care. The interviews were performed at a location chosen by the patient. Most of 
the participants preferred to be interviewed in connection with their clinical visit to their CF 
center. Four participants were interviewed at the CF center, and two participants choose to be 
interviewed at a location with no connection to the CF care. In-depth semi-structured in 
interviews were conducted, audio recorded and transcribed verbatim by a professional 
transcription service.  
4.4 MEASUREMENTS 
In the area of Mental health in CF has, as mentioned, anxiety and depression been in focus.  
However, the concept Mental health is, as described, broader defined and in the present 
project there is also an attempt to catch the aspect of wellbeing. To match the area of CF with 
regard to estimates of Mental health, and to conclude or exclude risk for impairment in 
mental health, prevalence and level of Anxiety and Depression was measured as a first step in 
Study I. In Study II we wanted to include the wellbeing aspect. A priority in the choice of 
measurements was that the instruments used should address the question of interest (as a 
whole or partly) in 1. a CF-population, or 2. a population with a somatic disease. This 
resulted in a decision to use a proxy for Psychological wellbeing (including measurements of  
anxiety and depression, and HRQoL, as a HRQoL measurement should reflect the 
“individual’ s subjective evaluation of her functioning and well-being”) (106). In Study III 
Anxiety and Depression were tested as predictors for the development in somatic parameters. 
In Study IV patient experiences were explored. 
Anxiety and Depression 
 In Studies I-III anxiety and depression were measured using the Swedish, validated version 
(107) of the Hospital Anxiety and Depression Scale, HADS (108) a well-validated (109) 
screening tool with good psychometric characteristics developed to identify cases of anxiety 
and depression in somatic populations. The questionnaire has two subscales, anxiety and 
depression, and consists of 14 items graded from 0 to 3. Anxiety and depression scores are 
obtained by summing the scores for each subscale, yielding values of 0 to 21. Each subscale 
has three ranges: 0-7 (non-cases), 8-10 (mild-moderate anxiety or depression) and 11-21 
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(moderate-severe anxiety or depression). The cut off-scores are defined on the basis of 
clinical psychiatric ranges for anxiety and depressive disorders.  
HADS data were used in Study I and Study III. In Study II HADS was used together with 
CFQ-R as a proxy for “psychological wellbeing”. 
Health related quality of life in CF 
Cystic Fibrosis Questionnaire-Revised (CFQ-R) (106) was originally developed in the United 
States. It is well-validated and widely used and has been translated into at least 34 languages 
(110). In Study II, HRQoL was measured using the Swedish translation (111) of the 
teen/adult version of CFQ-R. The instrument consists of 50 items across 12 domains 
reflecting different aspects of health-related quality of life in CF. Reply choices generally 
include ratings of frequency and difficulty on a scale graded from 1 to 4. Some items have 
more pronounced response alternatives: for example, “How do you assess your health right 
now?,” with answers ranging from 1 = excellent to 4 = poor”). Scores are standardized to a 
range of 0 to 100, with higher scores indicating better HRQoL. Questions concerning 
demographic factors (age, sex, marital status, educational level, and work/school situation) 
are also included. The questionnaire has shown robust psychometric properties (110).  
Psychological wellbeing  
In Study II a proxy of Psychological wellbeing was used as an outcome measure. Because 
associations have been found previously between HRQoL and anxiety and depression 
respectively among adult CF patients (67, 74) the measurements considered most relevant to 
reflect a proxy of psychological wellbeing in the present population was the HADS together 
with the HRQoL measurement CFQ-R.  
cftr mutation class 
Information about the participants’ cftr gene mutation class was retrieved from the Swedish 
National CF-registry, and used to study the  effects/impact of cftr mutation class on 
psychological wellbeing in Study II.  
Study II examined the effects of physical exercise on psychological wellbeing using self-
reported hours per week of physical exercise as the measurement. At the annual check-ups at 
Swedish CF-centers the physiotherapists collect the patients’ self-reported amount of physical 
exercise in hours per week. The physiotherapists’ protocol defines physical exercise as 
“planned exercise aimed to maintain/improve mobility strength, condition with a duration of 
> 30 min for adults.” This information is also stored in the Swedish CF registry, from which 
it was taken for study II. 
Somatic status 
In Study II a latent variable for medical status was created using the somatic measures Lung 
Function, Physical Working Capacity, Body Mass Index and Immunoglobulin G. These 
  25 
measures were used since they reflect clinical key aspects of medical status in CF; lung 
function, physical capacity, nutritional status, and chronic inflammation/infection. Data were 
retrieved from the CF National Registry and from patient records (described in the Procedure 
section). 
In Study III these measures were used as separate variables. 
Lung Function, FEV1 % predicted 
In Studies II and III lung function test was performed by dynamic spirometry. From measured 
forced expiratory volume in one second (FEV1) in litres, percentage of predicted values 
(FEV1%) were calculated using Solymar and Hedenström reference equations for patients < 
19 and ≥ 19 years, respectively (112-114). The lung function test was performed according to 
European Respiratory Society (ERS)/American Thoracic Society (ATS) recommendations 
(115). 
Body Mass Index (BMI) 
In Studies II and III the BMI was used as a measure of nutritional status. BMI was calculated 
with the formula: BMI = Weight (kg)/Height (m)2   
Physical Working Capacity (PWC) 
In Studies II and III the participants physical capacity (watt/kilo) was measured with a 
cycle ergometer test for exercise testing performed on an electrically braked bicycle 
ergometer. The tests were performed at the Department of Clinical Physiology at 
Karolinska University Hospital Huddinge. 
Immunoglobulin G (IgG) 
In Studies II and III Immunoglobulin G was used as a measurement of chronic 
inflammation/infection and was analyzed by  standard methods of protein electrophoresis at 
the Karolinska University Hospital Huddinge clinical laboratories. 
Data gathered through semi structured in depth interviews 
Study IV used a qualitative approach and data were gathered through in-depth semi 
structured interviews. A semi-structured interview guide (Appendix 1) with open-ended 
questions was used together with follow up-questions to stimulate detailed narratives of the 
participants’ experiences. The interviews were digitally recorded and lasted between 25 and 
59 minutes. 
4.5 DATA ANALYSIS  
4.5.1 Study I   
To compare the Swedish CF sample data with already published data from the different CF 
and general populations, a dataset was simulated with the same characteristics (N, M, SD and 
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frequencies) (Table 2) as the present Swedish CF population as well as the other CF and 
general populations included in the study.   
Table 2. Descriptive statistics for the present Swedish CF population as well as other CF and general 
populations. 
    Age  HADS_A  HADS_D 
Population  N  M Range  M (SD) ≥ 8 (%)  M (SD) ≥ 8 (%) 
CF, Sweden (present)  129  30.4 18-70  5.5 (3.7) 27  3.0 (2.9) 9 
General, Sweden (107)  624  44.0 30-59  4.6 (3.7) 20  4.0 (3.5) 15 
General, Sweden (116)b  176  - 20-23  5.5 (4.0) 28.1a  3.1 (3.0) 9.5a 
CF, UK (74)   121  30.0 18-70  6.1 (3.8) 33  3.6 (3.3) 16 
CF, UK (73)  1779  - ≥ 18  6.1 (4.1) 34  3.4 (3.3) 13 
General, UK (117)  1792  41.5 18-91  6.1 (3.8) 33  3.7 (3.1) 11 
CF, Germany (63)b  343  - 21-50  4.9 (3.5) 22  3.2 (3.3) 12 
General, Germany (118)  4410  50.3 ≥ 18  4.7 (3.5) 21  4.7 (3.9) 24 
CF, Belgium (67)  57  26.7 -  5.6 (3.9) 30  3.5 (3.6) 13 
General, Netherlands (119)  199  39.9 18-65  5.1 (3.6) 24.4a  3.4 (3.3) 11.9a 
 
a Not presented in the article, predicted from the mean value. 
b Excluding the youngest age category 
 
In order to analyze whether there were any differences between CF patients and the general 
population in the different countries with regard to levels of anxiety and depression two 
separate three-way ANOVAs with Sex, Country, and Group (CF-patient/general population) 
as independent variables, and with either HADS anxiety or HADS depression as the 
dependent variable, were conducted. Binary logistic regression was used in order to analyze 
effects on the odds of having an elevated score (≥ 8) for anxiety or depression. Effects of age 
on HADS anxiety and depression, as well as the effects of anxiety and depression on each 
other, were analyzed with ordinary linear regression.  
4.5.2 Study II   
Study II used Structural Equation Modeling (SEM) to fit two different models to data. In the 
first model the associations between the manifest variable “cftr mutation class” and the latent 
variables “psychological wellbeing” (consisting of the observed indicators HADS and CFQ-
R scores) and “medical status” (consisting of the observed indicators FEV1 % predicted, IgG, 
BMI, PWC) were analyzed (fig 4). In the second model we analyzed the associations 
between the manifest variable “physical exercise” and the latent variables “psychological 
wellbeing” and “medical status” (fig 6).  
4.5.3 Study III   
Study III analyzed the effects of the development in the outcomes FEV1% predicted, BMI, 
PWC and IgG using Latent Growth Modeling. In the present Latent Growth Model, the 
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longitudinal observations of the medical parameters FEV1 % predicted, BMI, PWC and IgG, 
respectively, were regressed on a latent intercept and a latent slope. The intercept and the 
slope growth factors were, in their turn, regressed on the variables anxiety, depression and 
their interaction to analyze whether these had any association with the outcomes at baseline 
(= intercept) or the longitudinal development of the outcomes (= slope).  
4.5.4 Study IV   
The interviews were audio-recorded on an MP3 device and transcribed verbatim by a 
professional transcription service. The transcribed interviews were the units of analysis. In 
Study IV inductive content analysis (120) was chosen in order to answer the research 
question and to obtain both a description of what experiences the patients’ have of coping 
with the treatment regimen, and an understanding of how it is and what it means to have these 
experiences. Thus, both manifest and latent content analysis were conducted (120). The 
interviews transcribed into text documents were the units of analysis. The software NVivo 12 
was used in the analysis.  
Author LBE analyzed the text from the analyses and questions and uncertainties during the 
analysis were frequently discussed with ML, skilled in qualitative analysis. ML also reviewed 
the meaning units, codes, categories, subthemes and themes during the whole process to 
address trustworthiness of the analysis. The subthemes and themes were refined several times 
during the process. The authors LH, BM and KS reviewed the themes and subthemes, based 
on their different competences, and the results were further refined from their reflections. 
5 RESULTS  
5.1 STUDY I  
The participating Swedish CF-centers recruited 52 % of the potential participants – 72% in 
Stockholm, 53 % in Gothenburg and 21 % in Lund; N = 129, Mean age: 30.4 (SD 11.73, 
range 18-70), 50 % women; Mean FEV1 % predicted: 73.3 (SD 27.3, range 22-125). 
Binary logistic regression analysis showed no elevated risk for depression in the CF patients 
compared to the general population in any of the present countries.  
ANOVA showed that Swedish adults with CF reported a marginally higher degree of anxiety 
than the Swedish general population F(1, 927) = 4.56, p = .033, η2 = .005. This effect was not 
seen in any of the other countries (all ps > .19) included in the comparisons. However, this 
finding did not remain significant in the logistic regression analysis.  
The marginally higher level of anxiety in the Swedish CF sample was limited to the women; 
the women with CF reported a slightly higher degree of anxiety than did women in the 
Swedish general population F(1, 512) = 16.17, p = .007, η2 = .014. This effect was not found 
among the Swedish men F(1, 413) = 0.18, p = .676, η2 < .001.  
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Also the CF patients reported lower degree of depression than the general population in 
Sweden, F(1, 927) = 5.95, p = .015, η2 = .006, the UK, F(1, 3686) = 13.25, p < .001, η2 = 
.004, and Germany, F(1, 4751) = 45.32, p < .001, η2 = .009, but not in Belgium/Netherlands, 
F(1, 254) = 0.039, p = .844, η2 < .001.  
5.2 STUDY II      
The study recruited 75 % of the potential participants; N = 68; 46 % women; Mean age: 33 
years (SD 11.1, range 19-65), Mean FEV1 % predicted: 71.7 (SD 28.1, range 20.6 – 123.3). 
For outcomes reflecting aspects of psychological well-being the cftr mutation class × age 
interaction effect indicated that a psychological disadvantage tended to increase more with 
age among those having the more severe cftr mutation classes I and II; a substantial portion 
of this effect, >65 percent, was mediated via medical status. This means that the increase in 
the psychological disadvantage of homozygosity, or compound heterozygosity, for mutation 
classes I and II as patients get older is largely accounted for by a parallel increase in the 
medical disadvantages of homozygosity, or compound heterozygosity, for mutation classes I 
and II (fig. 5). 
 
Fig. 4 Illustration of model 1, with CFQ-R total score as outcome. The manifest (= observed) variables FEV1% 
pred, BMI, PWC, and lgG (reversed) were used as indicators of the latent variable medical status, and this latent 
variable is included as a mediator mediating the effects of the predictors group 1-3, age, and the group 1-3 ´ age 
interaction effect on CFQ-R total score. The effects are adjusted for the effects of sex, having a spouse/domestic 
partner or not, and level of education. The parameter values are standardized regression coefficients. † p < .10, * 
p < .05, ** p < .001 
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Fig. 5 The association between age and CFQ-R total score (left) and medical status (standardized to mean zero 
and standard deviation one) (right) for patients homozygous, or compound heterozygous, for Class I and II 
(filled circles and solid lines) and those not having these mutation classes (open circles and dotted lines). 
 
Physical exercise had a total positive effect on the variable psychological wellbeing, but >75 
percent of the effect is mediated by medical status. For no subscale was the direct effect of 
exercise significant, and in most cases it was even slightly negative. This may indicate that 
there would be no advantage from physical exercise on psychological wellbeing if not 
accompanied by a positive effect on medical status. 
 
 
Fig. 6 Illustration of model 2, with CFQ-R total score as outcome. The manifest (= observed) variables FEV1% 
pred, BMI, PWC, and lgG (reversed) are used as indicators of the latent variable medical status, and this latent 
variable is included as a mediator mediating the effect of the amount of physical exercise on CFQ-R total score. 
The effects are adjusted for the effects of sex, having a spouse/domestic partner or not, level of education, group 
1-3, and age. The parameter values are standardized regression coefficients. † p < .10, * p < .05, ** p < .001 
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5.3 STUDY III 
The study recruited 75% of potential participants; N = 68; 46 % women; Mean age: 33 years 
(SD 11.1, range 19-65), Mean FEV1 % predicted: 71.7 (SD 28.1, range 20.6 – 123.3).  
The effects of the intercept in 2002 and the slope for 2002-2007 on anxiety and depression in 
2008 are presented in Table 1 and the effects of anxiety, depression, and their interaction on 
the intercept in 2008 and the slope for 2008-2014 in Table 2. Measures of model fit indicate 
quite good fit of the models, especially for FEV1 % predicted. This good fit indicates that the 
outcomes are strongly associated with time.  
 
Fig 7: Illustration of the conducted Latent Growth Models were the natural logarithm of FEV1 is regressed on a 
latent intercept (I = predicted log(FEV1% pred) at baseline) and a latent slope (S = predicted change in the 
log(FEV1% pred) per year) for the two time periods 2002-2007 and 2008-2014. The intercept in 2008 and the 
slope for 2008-2014 are regressed on level of anxiety, depression, and their interaction. In a separate analysis, 
due to convergence problems, level of anxiety and depression were regressed on the intercept in 2002 and the 
slope for 2002-2007. Values for parameters a-d are presented in Table 3 and for parameters e-m in Table 4. 
 
Table 3. Effects of the intercept in 2002 and the slope for 
2002-2007 on level of anxiety and depression in 2008. 
Letters in parentheses correspond to parameters in Fig. 7  
Model fit presented at the bottom. 
Effect FEV1% IgG BMI PWC 
On Anxiety     
Int. 02 (a) -0.007 -0.006 0.003 0.017 
Slope 02-07 (c) -4.280 -3.137 -2.018 -6.122 
On Depression     
Int. 02 (b) -0.030 -0.015 0.006 0.030 
Slope 02-07 (d) -16.257† -10.236* -5.117 -11.789 
Model fit     
Chi sqr 31.9a 47.2a 56.1a 47.2a 
RMSEA 0.058 0.110 0.130 0.109 
CFI 0.991 0.961 0.934 0.970 
TLI 0.991 0.958 0.929 0.967 
* p < .05, † p < .10, a DF = 26 
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Table 4. Effects of anxiety, depression, and their 
interaction on the intercept in 2008 and the slope for 
2008-2014. Letters in parentheses correspond to  
parameters in Fig. 7 Model fit presented at the bottom. 
Effect FEV1% IgG BMI PWC 
On Intercept 08     
Int. 02 (e) 1.248* 0.814* 1.189* 0.810* 
Anx (f) 0.021 -0.004 -0.004 0.002 
Dep (h) -0.010 -0.014 -0.034† -0.022† 
A × D (j) -0.005 -0.022 -0.001 0.000 
On Slope 08-14     
Anx (g) -0.014 -0.008* 0.003 -0.001 
Dep (i) 0.003 0.006 0.002 0.002 
A × D (k) -0.009* 0.001 0.004 0.002 
Slope 02-07 (l) -0.073 0.839 -0.443 0.715* 
Int. 02 (m) 0.018 0.017 0.073 0.009 
Model fit     
Chi sqr 205a 227a 275a 224a 
RMSEA 0.112 0.124 0.147 0.122 
CFI 0.944 0.913 0.872 0.927 
TLI 0.941 0.909 0.865 0.923 
* p < .05, † p < .10, a DF = 111 
 
Anxiety at baseline, 2008 showed a prospective association with a worse development in lung 
function, FEV1 % predicted, 2008-2014, especially when anxiety is combined with some 
level of depression – as indicated by a significant anxiety×depression interaction effect on 
the development in FEV1 % predicted (Table 4). However, this finding might be overly 
influenced by two participants as can be seen in Fig. 8. Anxiety had no association with past 
and present levels and developments in any of the outcomes. Furthermore, the higher the 
degree of anxiety in 2008 the more IgG tended to decrease between 2008-2014. 
 
Fig 8: The association between anxiety, measured in 2008, and the development in lung function between 2008 
and 2014, separately for those with no depression (≤ 2 on HADS-D, open circles and dotted line) and some 
depression (≥ 3, filled circles and solid line). 
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Depression, on the other hand, had no prospective associations with the development in the 
outcomes between 2008 and 2014. However, the level of depression in 2008 had some degree 
of association with the development in FEV1 % predicted and IgG between 2002 and 2007 
and with predicted BMI and PWC in at baseline, 2008.  
5.4 STUDY IV 
The study recruited 52% of potential participants; N = 12; 58 % women; Age: MD 33 years, 
range: 32-55, FEV1 % predicted: MD=46, range: 30-96.  
Three themes emerged from the analysis comprising a total of nine subthemes:  
“Priorities and management of health – a life condition”, “Aspiration for and a possibility of 
a “normal life”, and “The CF center as a partner in the life condition” (Fig. 9). 
 
Fig. 9 The three themes and their subthemes that emerged from the analysis. 
Theme: Prioritize and manage health – a life condition 
This theme deals with the participants’ experiences of  the CF treatment regimen as a 
demanding part of life constantly present in different forms, foremost of which is the daily 
self-care, which has a substantial impact on their lives. This theme had three subthemes 
reflecting different aspects of the life condition: 
“Prioritization of health means limitations and dependence”: The prioritization of health 
management means that they always are limited in their choices, daily life and spontaneity. 
They also perceived a dependency of others, to maintain stable self-care routines. Also an 
ongoing attention and scanning of their own somatic health was also perceived as limiting. 
“Life and death - constantly selectable through prioritization”: There was a consciousness 
that without treatment and regular self-care, the life would be shorter, especially in cases of 
more progressed disease. The fear of the disease and death were also perceived as a 
Theme: Prioritize 
and manage health -
a life condition
'Prioritization of 
health means 
limitations and 
dependence'
'Life and death -
constantly 
selectable through 
prioritization'
'Concerns 
associated with 
the prioritizations 
of health'
Theme: Aspiration 
for and a possibility 
of a “normal” life"
'Living a normal 
life'
'Comparison with 
"healty people'
'Conflict between 
prioritization of 
health and  a 
'normal life'
Theme: The CF 
center as a partner in 
the life condition
'Need to be met as 
a human subject, 
not as an object 
with a disease'
'Need for 
validation and 
understanding'
'Need of 
influence, 
continuity and a 
trustful alliance'
  33 
motivating factor to self-care. Deterioration of health despite maximized treatment was 
perceived as very stressful and raised hopelessness and existential issues of life and death. A 
strong desire to live as long as possible was expressed as a motivation to self-care.  
“Concerns associated with the prioritizations of health”: Experiences of worry, anxiety, 
anger, frustration and bad conscience associated to the prioritizations of health was described. 
There were also anger and frustration associated with the self-care, particularly in cases of 
more progressed disease. Experiences of bad conscience and guilt associated with the self-
care was consistently described. Experiences of not having succeeded in establishing a 
sustainable long-term approach to the self-care were described as very stressful. 
Theme; Aspiration for and a possibility of a “normal life” 
This theme reflects the participants' relationship to a life they called a ‘normal life’ or 
described as a life ‘healthy’ or ‘all other’ people live. This life was seen as possible to 
achieve, or to strive for. The theme had three sub-themes.  
“Living a normal life”: Focus on living ‘normally’ had, for some, been a helpful approach 
both physically and mentally as long as the disease was under control. In some cases, a 
perceived pressure to live normally was as stressful and raised feelings of worthlessness if not 
managed. In cases of more progressed disease living a normal life was perceived as costly in 
terms of time and energy that had to be spent on health management. Trying to live a ‘normal 
life’ through denial of the disease to protect both oneself and other people was also described; 
a ‘normal life’ was lived but the self-care was neglected. 
“Comparison with "healthy people”: To compare oneself with “healthy people”, especially in 
descriptions of self-care in the form of for instance going to the gym could be perceived as 
stressful. Conversely, in some cases participation in sports/exercise with healthy people had 
given self-confidence and a sense of being like everyone else. 
“Conflict between prioritization of health and  a 'normal life”: The participants consistently 
described contradictions between working and prioritizing health, which resulted in increased 
stress. Another conflict area was combining parenting with the prioritization of health, 
especially when having small children. These conflicts resulted in stress and bad conscience. 
Theme: The CF center as a partner in the life condition  
This theme reflected the participants relationship with the CF center as a partner in the life 
condition rather than an ordinary health care unit. Central needs for the participants in the 
interaction with the CF center were represented in three sub-themes: 
“Need to be met as a human subject, not as an object with a disease”; This was perceived 
when the healthcare staff had a listening approach and an ability to balance recommendations 
based on the individual's current situation and functioning. Continuous long-term support in 
finding self-care plans sustainable in everyday life was very important. When the need of 
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being met as a human subject was not fulfilled additional stress and bad conscience was 
experienced.  
“Need for validation and understanding”: with regard to the practical, psychological and 
existential demanding aspects of CF. There was also a need of that the health care staff has to 
consider that CF naturally generates fear, stress and frustration which affects the behavior and 
in the long run the personality of the person with the disease.  
“Need of influence, continuity and a trustful alliance”: The partnership with the CF center 
should be based on continuity, influence and trustful treatment alliance.  This was obtained 
through regular contacts with healthcare staff based on honesty and clarity about the health 
status, and ongoing discussions with regard to health management, where participants could 
use their experience and knowledge of CF. 
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6 ETHICAL CONSIDERATIONS    
Investigating psychological symptoms in people must always be made in a professional and 
sensitive way, and the aim must be clearly explained to each participant.  
CF patients suffer from a life-shortening disease, and posing questions about psychological 
issues to people living under these conditions is a sensitive matter. Questionnaires and 
interviews were used, and some people may have felt uncomfortable or stressed by the 
questions or their results. For example, some questions in the questionnaires explicitly target 
issues such as self-harm/suicide, the impact of symptoms, impact on social life, etc., and may 
have been psychologically painful to answer. Furthermore, such studies may include people 
who are in very poor health, and this raises the issue of whether it is ethically sound to assess 
psychological status and quality of life in such participants.  
In this project we handled these ethical considerations by having licensed psychologists 
administer and assess the results of the questionnaires. Licensed psychologists also conducted 
the interviews, as they are professionally trained in both interview techniques and in handling 
sensitive information. Furthermore, a psychologist followed up with participants who 
reported elevated scores for psychological symptoms or poor quality of life and offered 
further assessment and treatment. All participants were informed of the possibility of 
contacting the psychologist if they had any further concerns or questions regarding their 
participation. 
Another ethical concern was that the psychologist performing the project also worked as a 
clinician at the CF clinic. Through their role in data collection, this psychologist has access to 
information about participants who may later be their patients. The opposite is also an ethical 
concern: patients who had previously been helped by the researchers may have felt forced to 
participate in order to please them. Earlier clinical contact with the researchers may also have 
affected their answers on the questionnaires. This issue of the researchers’ double role was 
especially delicate in the interview study. We therefore choose to have two psychologists 
from the CF center conduct the interviews. Thus, the participants were interviewed by a 
researcher with whom they had no prior treatment relationship. 
CF centers are research intensive, and because patients visit them regularly from the day of 
diagnosis (usually in early childhood) until they die, they are asked to participate in different 
studies on multiple occasions. It is well known that treatment burden and symptom burden 
are high for CF patients. A final ethical question raised concerns the total “research burden” 
on patients. If future projects focus on the psychological aspects of CF, this might increase 
the experienced total burden of the disease, since it greatly affects patients’ personal integrity 
and privacy. However, patients benefit in the long run from participating in research projects 
through the development of improved treatment and management of the disease and better 
health, prognoses, and survival.  
The Central Ethical Review Board, Stockholm, approved the studies, ethical permission nr 
2007/1266-31 (Study I-III) and nr 2016/2425-31 (Study IV). Due to smaller changes in the 
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recruitment procedure, the board was informed about this by email and regular mail, nr 
2018/2469-32. The participants gave their written consent to participate prior to the studies. 
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7 GENERAL DISCUSSION  
The overall objective of this thesis was to investigate mental health among adults with CF, 
and to explore their experiences with the CF treatment regimen used in Sweden and thereby 
increase the knowledge about how the multiprofessional CF care team can facilitate and 
support adult CF patients in maintaining mental health.  
7.1 SUMMARY OF THE MAIN FINDINGS 
Study I found that there was no elevated risk for anxiety or depression in either the Swedish 
adult CF population or adult CF populations in the three other European countries used in the 
comparisons. In the Swedish CF sample women reported higher levels of anxiety than 
women in the Swedish general population, but no difference was seen among the men. 
Study II showed that adults with more severe CF mutations tended to become susceptible to 
poor psychological wellbeing with older age. However, this effect is indirect and to large 
proportion mediated by medical status. There is no direct effect of severity of mutation class 
on psychological wellbeing; instead, disease progression seems to be more pronounced for 
those who have severe mutations, which in turn can have an effect on psychological 
wellbeing. In addition, among the adults with CF, those who engage in high amounts of 
physical exercise maintain their psychological wellbeing only so long as they also maintain 
their somatic health status.  
Study III showed that anxiety, especially when combined with some level of depression, can 
serve as a predictor of a steeper decline in lung function over time, despite there is no 
elevated risk for anxiety and depression in the Swedish adults with CF as showed in the 
cross-sectional Study I. Depression had no prospective association on development in lung 
function. However, it did have an association with current lung function and past 
development of lung function.  
Study IV found that the experiences of the treatment regimen were reflected in three themes: 
prioritize and manage health—a life condition, aspiration for and the possibility of a normal 
life, and the CF center as a “partner in the life condition.”  
The theme “prioritize and manage health – a life condition” reflected that the adults with CF 
experiences of the treatment regimen as a demanding part of life constantly present in 
different forms, foremost of which is the daily self-care, which has a substantial impact on 
their lives.  
The theme “aspiration for and the possibility of a normal life” showed the patients’' 
relationship to a life they called a ‘normal life’ or described as a life ‘healthy’ or ‘all other’ 
people live. This life was seen as possible to achieve, or to strive for. 
“The CF center as a “partner in the life condition” was a theme describing the patients’ 
relationship with the CF center as a partner in the life condition rather than an ordinary health 
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care unit, and highlighted central needs for the participants in the interaction with the CF 
center 
7.2 INTERPRETATION OF THE MAIN FINDINGS 
The results in Study I point to no elevated risk for anxiety or depression in either the Swedish 
adult CF population nor he adult CF populations in the three other European countries in the 
comparisons. This is contrary to conclusions of some other studies on the subject, which have 
claimed higher rates of and risk for anxiety and depression in CF patients (63, 69, 72, 77). 
Our results are also contrary to what is seen in other populations with chronic diseases (7). 
Our results are, however, in line with results from one study performed in the UK and one 
study from Belgium (67, 73). However, it should be noted that the countries included in our 
study are wealthy and providing public/universal health insurance systems, possibly 
eliminating stressors that may affect mental health. Furthermore, previous studies (121, 
122) have shown differences across European countries with regard to availability of 
specialist CF care, and demography, health status and mortality in CF populations. 
Generalizing these results to other CF populations in other countries should therefore be 
made with caution. 
The Belgian, German and the large British study included in our analyses, and also our 
Swedish CF sample data used the same protocol and measurement (HADS), as they were all 
part of the multicenter TIDES study. However, the analyses differ between the studies, and 
not all of them include general population data in the comparisons. This is one possible 
explanation for the differences in the conclusions from the studies.  
In our Swedish sample, women with CF reported higher levels of anxiety than women in the 
general population, which contributed to marginally higher levels of anxiety among the 
Swedish CF-patients. As mentioned, the Swedish CF-population as a whole has a good health 
status and high survival rate (3), and these factors therefore cannot be possible explanations 
for the elevated anxiety level. Instead it might be explained by differences in treatment 
regimens. As described in the introduction, the Swedish treatment regimen in the 1980s 
added some key treatment components and strategies to the existing international CF 
treatment guidelines. These treatment components were, and still are, largely managed by 
patients in their daily lives, which might make the total treatment burden and responsibility 
more stressful and anxiety-provoking for Swedish CF patients. However, this does not 
explain why elevated anxiety only is seen in Swedish women. We should also note that 
anxiety levels among Swedish women with CF are lower than the cutoff score for mild 
anxiety. This question needs to be explored in greater depth.  
The results from Study II add a new perspective to existing knowledge about the association 
of cftr gene mutation class and medical outcomes (22, 123). Among those with the more 
severe cftr mutation class there is an association between age and poor psychological 
wellbeing with a parallell deterioration of health. Our findings also indicate that adults with 
CF obtain a psychological benefit from physical exercise only as long as their somatic health 
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is maintained. When this is not the case, exercise has a slightly negative impact on 
psychological wellbeing. These findings together illustrate how adults with a more severe 
form of CF can enjoy relatively stable psychological wellbeing so long as their somatic health 
(medical status) is maintained. 
Study III was the first longitudinal study to investigate the effects of both anxiety and 
depression on somatic status over time in adults with CF. In the cross-sectional Study I, no 
elevated risk of anxiety and/or depression was seen in adults with CF, but the outcomes from 
the longitudinal Study III indicate that anxiety in combination with some level of depression 
may predict a steeper decline in lung function. This finding is of interest, as it highlights a 
prospective association between a mental health variable and development of a somatic 
parameter - in this case, lung function. An earlier study have studied, and found, associations 
between depression only and lung function over time (78).  However, our study does not 
allow us to explain our found association with any certainty. Perhaps it is due to the nature of 
anxiety as an emotion that serves to detect future potential danger (58). Anxiety may be 
triggered in patients experiencing signs of deteriorating health even before such deterioration 
can be measured, and it may serve to prepare the person to meet and tackle it. Another 
possible explanation is that anxiety may lead to avoidance of anxiety-provoking stimuli - in 
this case, contexts related to CF such as treatment. When adding to the panorama depressive 
symptoms such as feelings of hopelessness and loss of energy and depressive behaviors such 
as withdrawal from activity and avoidance, patients with this combination may have a 
diminished capacity for self-care and thus will hypothetically have a faster decline in lung 
function.  
In study IV the sample is quite unique, adults who are now middle-aged and who were part of 
the first generation of patients treated according to the Swedish treatment regimen 
implemented in the 1980s. The results show how prioritization of the health management is a 
life condition and a matter of life or death for this group. To be physically active and to eat 
healthily are parts of WHO’s health recommendations for all people (124). For people with 
CF, however, failure to follow specific lifestyle recommendations results in a deterioration of 
health. This leads to health-related anxiety and stress, especially when it comes to prioritizing 
health through self-care. Patients also describe hypervigilance with regard to somatic 
symptoms. However, compared with, for example, the somatically healthy population with 
anxiety (125), hypervigilance in the case of CF patients is adaptive insofar as it guides 
decisions with regard to health management. For the individuals dealing with CF, the 
prioritizing of  health also means limitations and dependence. The life condition therefore 
also can cause stress, worry, anxiety, bad conscience, guilt, frustration, and sometimes 
feelings of hopelessness.  
The results of Study IV also indicate that the patients have insight into the severity of the 
disease; the CF health care have through the self-care given them tools to achieve a longer 
and healthier life, and they hold great responsibility for their health and self-care. When 
coupled with the aspiration and possibility of living a normal life, a stressful and anxiety-
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provoking conflict can emerge. This is in line with an earlier study concluding that adults 
with CF have a psychosocial burden while they try to live “normal lives” and at the same 
time have to adhere to the complex treatment regimen (55). This is especially true when 
patients confront deterioration in their health. Reactions of stress and anxiety should be seen 
as normal in this context and not pathological. They are natural correlates of the challenging 
life circumstances of living with CF, and the CF care should address such reactions in the 
regular clinical visits.  In patients’ eyes, the CF center is a partner in the life condition and not 
just a health care unit. When patients’ central needs with regard to disease management and 
support are fulfilled by the center they feel met as “human subjects and not “objects with a 
disease”. They get psychologically validated and understood with regard to the challenges of 
life circumstances for persons with CF, and they perceive that they have a trustful alliance 
based on continuity and influence, it really helps patients cope with their life condition.  
7.3 OVERALL REFLECTIONS 
Taken together, the results from these studies give a clearer and updated picture of the 
psychological aspects of CF in adults. The patient perspective that emerges from Study IV 
allows us to better understand the results of the remaining studies in the project. Study I 
shows that as a whole, adults with CF do not have an elevated prevalence of anxiety or 
depression. In Study IV, one of the themes—aspiration for and the possibility of a normal 
life— highlights the importance, possibility, and meaning of living a normal life in areas such 
as employment and relationships, despite the disease. Patients also mentioned this “normal 
life” as a factor that contributed to their overall psychological wellbeing, maybe reflecting the 
non-risk of anxiety and depression. However, patients found points of conflict between 
achieving a normal life and prioritizing their health, which creates stress. It is possible that the 
slightly elevated anxiety levels found in Swedish women with CF reflect this stressful 
conflict that emerges as an effect of the burden of being responsible for one’s own treatment. 
However, as this elevated level of anxiety is seen only in the women this is a very cautious 
interpretation. 
Study II found that psychological wellbeing tended to decrease with age, in parallel with 
deterioration of health, among those individuals with more severe mutation classes. Study 
IV’s interviews of middle-aged patients with more severe mutation classes uncovered 
descriptions of their experiences of deteriorating health that align with this finding from 
Study II. When the disease progresses and the self-care and treatment burden increases, the 
interview subjects in Study IV, through the subtheme concerns associated with the 
prioritization of health, expressed how they felt stressed and anxious and experienced 
feelings of hopelessness. This aligns with the results of Study II. Physical exercise had an 
effect on psychological wellbeing only as long as somatic health was maintained or 
improved. Where this was not the case, the effect of physical exercise on psychological 
wellbeing was negative, although not significantly so. If we generalize this finding for 
physical exercise to other self-care efforts, we can link this result to the subtheme concerns 
associated with the prioritization of health in Study IV.  
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The results of Study III might also be further understood in light of Study IV. However, this 
requires a very cautious interpretation. In Study III, anxiety together with depression was 
seen to have a negative prospective association with changes in lung function. Perhaps 
anxiety may be an expression of patients’ sense of personal responsibility, the easily-
triggered guilt of not doing enough that was described in Study IV. From a psychological 
perspective, such a situation may lead to avoidance. When combined with feelings of 
hopelessness and resignation described in Study IV, and that in Study III may indicate some 
level of depression, that could potentially have a negative impact on self-care efforts, and in 
the long run thus a steeper decline in lung function.   
From a health psychological perspective, the results of this thesis illustrate the stress and 
adjustment in people with chronic illnesses and give us a deeper understanding of how this 
can manifest in people with CF. Despite the possibilities of achieving a normal life, the 
disease and its treatment are stressors on individuals, and as such they have a psychological 
impact. In the light of health psychology, stress reactions arising from the life circumstances 
of CF are a signal to the individual to adjust to the stressful condition: to address the stressful 
situation and choose life and health by performing the actions required to manage one’s 
health. An alternative is to avoid the stressor, and thus avoiding health management actions, 
and in the long run causing faster deterioration and shortening one’s lifespan. The results 
show that adjustment to stress by prioritizing health, and thus achieving relatively stable 
psychological wellbeing, is possible as long as somatic health can be controlled. However, 
the results also show that patients arrive at a point were further adjustment is not possible or 
cannot be achieved without great cost. In this situation, patients are at risk for worsening 
psychological well-being, and here the need for a well-functioning partnership with the CF 
care team is pronounced. 
7.4 METHODOLOGICAL CONSIDERATIONS AND LIMITATIONS OF THE 
FINDINGS 
Studies I–III used HADS scores as a measurement of anxiety and depression. In the planning 
stage, HADS was considered the most appropriate scale, especially as it was developed for 
use in populations suffering from somatic illnesses. However, HADS has been found not 
being sufficiently sensitive in the detection of depression (126), and also in CF populations 
(127). HADS is also a screening instrument and not a diagnostic tool. In the present project, 
as well as in the literature on anxiety and depression in CF patients, it would be more 
appropriate to use terminology other than anxiety and depression with regard to HADS 
scores: for example, indication of anxiety/depression. It should also be noted that the HADS 
score is based on self-reported data, not on clinical diagnostic data.  
In Study I, the representativeness of the sample with respect to the entire Swedish CF patient 
population was negatively affected by the very low response rate at one of the participating 
sites, and selection bias can therefore not be ruled out. The Swedish general population data 
were taken from two studies (107, 116) with different age ranges so as to better match the 
Swedish CF sample, and our comparisons may therefore have been affected by 
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methodological issues and potential changes in anxiety and depression prevalence over time. 
One of the studies also concluded that the reported scores differ depending on the method of 
data collection (116). 
In one of the Swedish studies using HADS normative data (107), data were collected in one 
region in Sweden and may not be representative of the total Swedish population. Another 
limitation is the use of existing studies with HADS normative data instead of matched control 
subjects. Furthermore, the normative samples also differ from those of the corresponding CF 
populations with regard to their characteristics. For example, some of the general population 
data are older than the corresponding CF population data, and mean ages vary and are higher 
than in some of the CF populations used in this project. The Belgian CF-data were compared 
with normative data from a Dutch study (119), since the authors of the Belgian CF article 
(67) used that study as a reference for their general population data. However, we considered 
it necessary to include other European countries and their corresponding normative data as a 
comparison in order to put our Swedish results into context. This was especially important 
given the lack of comparisons with general population data in the TIDES study (69). It was 
also advantageous to include previously published studies in this study’s comparisons, since 
given their formulation within the broader TIDES initiative the published studies, as well as 
our Swedish arm, had all used HADS as their measurement interest and employed similar 
study protocols. 
In Study II the terminology and descriptions in existing analyses are somewhat unclear; the 
analyses showed that the proxy for psychological wellbeing did not have the expected 
associations. We performed the same analysis with the HADS and CFQ-R separately and 
found that CFQ-R - health-related quality of life - did have the expected associations. We 
continued to use the term psychological wellbeing in the paper, however, which is rather 
misleading, since the measurement assessed health-related quality of life. It would also have 
been better to more clearly describe the additional analyses and to describe the lack of 
significant interaction effects with regard to the HADS and the proxy for psychological 
wellbeing. It should have been stated that CFQ-R, together with HADS, does not seem to 
work as a proxy for psychological wellbeing. However, in the planning stage of the study it 
was considered appropriate (from the priorities with regard to the choice of measurement 
described in the measurement section) to use this proxy. Interestingly, in a very recent study 
associations have been found between positive ‘mental health and wellbeing’ and almost all 
the CFQ-R domains (90). Because the term psychological wellbeing is used in the published 
paper, it was retained for use in this thesis. The reader should, however, consider that when 
the term psychological wellbeing is used with regard to Study II, it should be understood as 
actually referring to the closely related term health-related quality of life. 
The sample size and groups in Study II and III were small which negatively affect the power 
in the studies, and a cautious interpretation of the results is therefore required. However, they 
presented good representativeness of the present CF center. When studying rare diseases 
there are difficulties in general with regard to sample sizes and power. One solution should be 
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more multi center studies, but the single-center study design facilitated setting similar 
preconditions for all study participants with regard to, for example, treatment regimen. It 
might also be interesting to replicate these studies at larger CF centers or in countries with 
larger CF populations. For example, in Study III the anxiety´depression interaction effect 
was strongly influenced by a few participants in a subgroup of severely ill patients. This 
effect might be more pronounced in samples with a larger proportion of severely ill patients 
or in larger samples. 
However, regardless of the CFQ-R subscale used in Study II, the effects found were very 
similar. This indicates that the results are quite stable. The participants completed the HADS 
and CFQ-R questionnaires in the presence of a psychologist or social worker and reported 
their estimated amount of physical exercise directly to a physiotherapist, which might have 
influenced their scores and estimations. Furthermore, in some cases the amount of physical 
exercise and certain of the somatic parameters were not measured at the same clinical visit as 
when the questionnaires were completed.  
Because the parameters used in the latent variable medical status are central clinical measures 
of CF patients’ somatic status, it would also have been more appropriate to call the latent 
variable somatic status. In this latent variable there is a low correlation between BMI and the 
three other manifest variables. BMI should therefore not properly have been included in the 
latent variable medical status. However, BMI was included because it is a key parameter used 
in the clinical assessments of the CF patients’ somatic status. 
To estimate the effects of anxiety and depression on clinical somatic status over time, anxiety 
and depression should ideally be measured annually, which was not done in Study III. It is 
therefore not possible to draw any robust conclusion from these results. However, it is an 
important finding worth further study.  
In Study IV, all potential participants at the CF center - 23 patients were asked to participate, 
but 12 ultimately did. We therefore cannot rule out the possibility that the data are not 
sufficiently saturated. However, the sample is unique, as it consisted of approximately half 
the center’s middle-aged CF patient population who had not received transplants and who 
possessed the more severe cftr mutation classes. Furthermore, the participants were recruited 
at one CF center only; we should therefore only cautiously generalize the results to other CF 
centers, especially in other countries with different treatment regimens and/or health status in 
the CF population. However, because Swedish CF centers have the same treatment regimen, 
the results could possibly be used to understand the needs of middle-aged patients also in 
other Swedish CF care centers. Some of the needs with regard to CF care that emerged in this 
study might be applicable in care settings for chronically ill people in general.  
The interviews in Study IV were conducted by psychologists from the CF center; however, 
the specific interviewer did not have any previous clinical contact with the participants they 
interviewed. A majority of participants preferred to be interviewed in connection with their 
clinical visit. These close connections to the CF center might have influenced the information 
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that participants shared in the interviews, but we do not expect this had a negative impact on 
the quality of the interviews. The psychologists’ knowledge of CF may also possibly have 
contributed to some bias in their understanding of the participants’ responses. The interviews 
were conducted in Swedish and the results are therefore not inclusive of the perspective of 
patients speaking other languages i.e. are from other countries/cultures.  
A strength in Study IV is the researchers’’ different competences, and also their different 
relationships to/previous experience of the CF patient group, which ensure the 
trustworthiness (120) of the study. Two of the researchers have previous clinical experiences 
of the patient group (psychologist and medical doctor). The other three researchers have no 
earlier experiences of working with CF patients (psychologists and physiotherapist). There 
also was a further psychologist who conducted the majority of the interviews and was not 
involved in the analyses. This would also have minimized the risk for researcher bias. 
7.5 CLINICAL IMPLICATIONS  
The studies in this thesis together contribute to increased systematic knowledge about the 
mental health aspects of CF and the patient experiences of the CF treatment in the growing 
adult CF population. The participants in this thesis were, to a large extent, born at a time 
when Swedish people with CF got severely ill and died at young age, and CF patients in 
general were hospitalized for longer periods and were unable to have a job or go to school. 
Centralized care and multidisciplinary treatment has - together with progress in biomedical 
treatment options in different areas - improved the health status and life expectancy of the 
patient population. With the biopsychosocial model of health in mind, there are certain 
clinical implications in the area of psychology that emerge from the results of the this project. 
CF care in Sweden has made substantial progress in giving patients the tools to assume 
responsibility for their health and manage it through self-care, and it has also given patients 
support and the possibility of living a normal life. However, from a health psychological 
perspective, CF care should be more active in continuously supporting patients in their 
adjustment to the different phases of the disease trajectory, especially when in the later stages. 
CF care should also develop strategies based on health psychology to support the growing 
group of adult patients so they can cope in adaptive ways with the normal, but also painful, 
psychological reactions of stress and worry that self-care and disease can inflict. This patient 
group is new and will increase in the future, new cftr-modulating drugs will probably further 
improve health outcomes and CF care must adapt also to changing needs with regard to 
mental health in this patient group.  
This project shows the importance of including patient perspectives in order to arrive at a 
balanced view of the questions of interest: that is, to not only study patients as objects with a 
disease, as was the methodology in Studies I–III, but also (as was done in Study IV) as 
subjects, as humans who have unique experiences of living with CF. This approach can be 
further used in improving the understanding of, and thus the way to address the adherence 
question in adult with CF. Study IV offers a deeper understanding and a broader perspective 
of the mental health aspects of CF in adults, and its clinical implications can thus go beyond 
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the existing care model. A multidisciplinary CF care approach provides appropriate care with 
regard to objectively measured outcomes. However, it is not clear, from a patient perspective, 
that it fulfills the needs of continuity, influence, and a trustful alliance highlighted in this 
project. The current form of CF care neither guarantees that patients are seen as human 
subjects nor that patients are psychologically validated or understood from their perceived 
situation or condition. Patients’ descriptions of their needs with regard to the CF centers are 
in line with the person-centered care (PCC) model (128), which is now proposed by Swedish 
Association of local authorities and regions to become the current care model in Sweden 
(129). PCC emphasizes the partnership between patient and care provider, and the patients’ 
viewpoint and narrated experiences of their condition and life situation is the center of care. 
Furthermore, the patient is actively involved in their care process and shares in decision-
making and strategizing to ensure continuity of the care process. PCC could be applied in CF 
care, as it is especially suitable for the care of chronic illnesses and also has a potential to 
improve health outcomes, reduce patient stress, and increase patient satisfaction (128). 
7.6 FUTURE PERSPECTIVES 
As the development of CF treatment goes on and changes the health outcomes and conditions 
for the patient group an ongoing evaluation of mental health outcomes is suggested. Mental 
health screening, according to international guidelines, have been implemented in the 
Swedish CF-care in recent years, and updated studies of associations between psychological 
and somatic parameters can be conducted. However, research in the area of mental health in 
CF should in the future widen the perspective and include also the wellbeing aspects of 
mental health, which is highlighted also in a very recent study (90).  
Including the patient perspective through parallel qualitative studies with quantitative ones to 
gain a broader and deeper knowledge of the questions of interest has in this project been 
shown to be necessary for a deeper understanding of the mental health aspects of being adult 
with CF. Introducing PCC and care strategies based on findings from this project would give 
opportunities to follow up studies exploring patient satisfaction, level of stress and mental 
health and patient experiences in the present patient group. 
Future research in the area of mental in CF would probably benefit from having a clearer and 
more distinct theoretical framework, an umbrella that focuses on how biology, psychology, 
behavior and social factors influence a lifelong disease as CF. Although, the field of health 
psychology is still quite young, it has emerged to help changes in health in the population 
over all, by looking at behavioral patterns that underlie disease and death. This would be 
possible also in adult CF populations, and would probably give valuable knowledge to further 
develop. The CF care is organized in multiprofessional care teams and should out from the 
biopsychosocial model of health have good prerequisites to use a more pronounced health 
psychological approach for further improvements of health in the adult CF population.  
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8 CONCLUSIONS 
The studies in this thesis have together contributed with increased knowledge and 
understanding about mental health aspects in adults with CF. As a whole group, there is no 
elevated risk for impairment in mental health with regard to anxiety and depression. 
However, women with CF should be seen as vulnerable for elevated anxiety. Furthermore, 
individuals with genetically more severe CF with age get tend to get vulnerable for poor 
psychological wellbeing, and also those who are performing a high amount of physical 
exercise without maintaining their somatic health. Over time anxiety, when combined with 
some level of depression, seems to give a steeper decline in lung function. These mental 
health aspects can be deeper understood from the perspective that prioritization of health is 
(literally) a life condition for adults with CF, and that the aspiration for and possibility for a 
‘normal life’ can result in stressful conflicts, especially when health is deteriorating. In the 
coping with the life condition the CF-center is seen an important partner.  
Clinical implications should focus on the individuals vulnerable for poorer psychological 
wellbeing and supporting adjustment to the different phases of the disease trajectory through 
a health psychological approach in the CF-care. The CF care should also benefit from 
including the patients’ perspective to larger extent through PCC.  
Future research in the area of mental health in CF should broaden the perspective and focus 
also on the wellbeing aspects, and would benefit from have a more clearly defined health 
psychological framework thus including the study of behavioral patterns that underlie disease 
development and health. The multiprofessional CF care should have prerequisites for such 
studies where psychological, social, behavioral and biological associations are studied. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Bakgrund: Cystisk Fibros (CF) är en autosomalt recessivt ärftlig, livsförkortande sjukdom. 
Sjukdomen är medfödd, kroniskt progredierande och påverkar framför allt lungor och 
magtarmkanal. Den progressiva kroniska lungsjukdomen är den vanligaste orsaken till för 
tidig död. CF var länge en sjukdom där de drabbade dog i unga år. De senaste 40 åren har 
dock stora framsteg gjorts i behandling och strategisk vård vilket lett till en ökande andel 
vuxna med CF. I Sverige har CF-populationen som helhet jämfört med andra länder en god 
hälsostatus, låg dödlighet och en mycket hög andel vuxna. Det finns ännu inte någon bot för 
CF. Behandlingen, förebyggande och inriktad på symptom, är krävande och måste dagligen 
utföras av patienten själv. Då sjukdomen är progressiv blir behandlingen mer krävande ju 
äldre den drabbade blir och ju mer hälsan försämras. Vuxna med CF har således en betydande 
sjukdoms- och behandlingsbörda som medför stor inverkan på livet som helhet, vilket kan 
antas påverka det psykiska måendet. Då vuxna med CF är en ”ny” patientgrupp, finns inte så 
mycket kunskap om deras psykiska hälsa. En del studier, med olika utfall, har gjorts, mest 
med fokus på ångest och depression, dock varierar resultaten kraftigt. I Sverige har ingen 
undersökning gjorts vad gäller vuxna CF-patienters psykiska hälsa; ingen kan med säkerhet 
säga hur den gruppen mår.  
Syfte: Att i fyra studier bland vuxna med CF undersöka psykisk hälsa och upplevelser av den 
svenska CF-behandlingen, för att öka kunskapen om hur den multiprofessionella CF-vården 
kan stödja och underlätta för vuxna med CF.  
Metod och resultat: I Studie 1 framkom ingen ökad risk för ångest och depression i gruppen 
genom analyser med binär logistisk regressionsanalys. Studie II visade genom struktur-
ekvations modulering att de som har svårare former av CF med åldern, och parallell 
försämring av den fysiska hälsan, blir sårbara för sämre psykiskt välbefinnande. Likaså de 
som lägger mycket tid på behandling i form av fysisk träning (en grundbult i Svensk CF-
behandling) utan att vidmakthålla sin fysiska hälsa. Studie III visade genom latent growth 
modelling att (trots att risken för ångest och depression inte är förhöjd) ångest, tillsammans 
med depression, över tid hade samband med en snabbare försämring av lungfunktionen. I 
Studie IV intervjuades personer över 30 år om deras upplevelser av CF-behandlingen. Genom 
induktiv innehållsanalys framkom att prioriteringen av hälsan (bokstavligen) är ett livsvillkor. 
De intervjuade uttalade en möjlighet och en strävan efter att leva ett ”normalt liv”, men med 
stor inverkan av livsvillkoret/ prioriteringen av hälsan. CF-centret upplevdes som en partner i 
livsvillkoret, snarare än som en vanlig vårdmottagning.  
Slutsatser: Sammantaget kan skrivas att avhandlingen bidragit med ökad kunskap om 
svenska vuxna CF-patienters psykiska hälsa och upplevelser av CF-behandlingen. Som grupp 
har de ingen ökad risk för psykisk ohälsa i form av ångest och depression. De med svårare CF 
och högre ålder/försämrad hälsa, och de med ökad behandling/träning utan att bibehålla 
fysisk hälsa verkar däremot sårbara för sämre psykologiskt välbefinnande. Framtiden bör 
inriktas på att utveckla omhändertagandet av vuxna med CF genom personcentrerad vård 
samt genom att systematiskt uppmärksamma dem som kan vara sårbara för sämre psykiskt 
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mående. Då risken för ångest och depression är liten, bör också välbefinnande-aspekterna av 
psykisk hälsa undersökas. Den multiprofessionella CF-vården bör ha goda förutsättningar för 
fortsatta studier utifrån ett mer uttalat teoretiskt ramverk där samband mellan biologiska 
psykologiska, sociala och beteendemässiga faktorer studeras.   
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